- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: Navamepent (RX-10045) is a stable resolvin E1 analogue, that is being investigated for clinical efficacy in occular inflammation . Chemically this is an isopropyl ester prodrug of resolvin E1 (an agonist of the chemerin receptor). The chemical structure is claimed in patent US20140275247A1 (as Example 1001) . Findings from animal studies are reported in  and .
1. Cholkar K, Gilger BC, Mitra AK. (2016)
Topical delivery of aqueous micellar resolvin E1 analog (RX-10045).
Int J Pharm, 498 (1-2): 326-34. [PMID:26706439]
2. Gjorstrup P, Schwartz CE. (2016)
Compositions and methods for the treatment of inflammation.
Patent number: US20140275247A1. Assignee: ANIDA PHARMA Inc. Priority date: 13/04/2013. Publication date: 19/04/2016.
3. Hesselink JM, Chiosi F, Costagliola C. (2016)
Resolvins and aliamides: lipid autacoids in ophthalmology - what promise do they hold?.
Drug Des Devel Ther, 10: 3133-3141. [PMID:27729772]
4. Torricelli AA, Santhanam A, Agrawal V, Wilson SE. (2014)
Resolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRK.
Mol Vis, 20: 1710-6. [PMID:25558174]